Note: Lancet requires free registration prior to providing content.
A. “Amyloid {beta} deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study,” by Victor L. Villemagne, Samantha Burnham, Pierrick Bourgeat, Belinda Brown, Kathryn A. Ellis, Olivier Salvado, Cassandra Szoeke, S. Lance Macaulay, Ralph Martins, Paul Maruff, David Ames, Christopher C. Rowe, and Colin L. Masters, for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (Vol. 12, No. 4, April 4, p. 357-367).
www.thelancet.com/journals/laneur/article/PIIS1474-4422%2813%2970044-9/abstract
B. “Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial,” by Robert A. Hauser, Ann Hsu, Sherron Kell, Alberto J. Espay, Kapil Sethi, Mark Stacy, William Ondo, Martin O’Connell, and Suneel Gupta, for the IPX066 ADVANCE-PD investigators (Vol. 12, No. 4, April 4, p. 346-356).
www.thelancet.com/journals/laneur/article/PIIS1474-4422%2813%2970025-5/abstract
